Company Filing History:
1 out of 30 
1 out of 5,448 
1 out of 2 Years Active: 2021
Title: Inventor Spotlight: Wolf-Hagen Schunk from Berlin, DE
Introduction
Wolf-Hagen Schunk, a notable inventor based in Berlin, Germany, has made significant strides in the field of cardiovascular medicine through his innovative research and development. With a focus on compounds that show promise in treating cardiac diseases, Schunk has patented his findings, contributing valuable knowledge to the medical community.
Latest Patents
One of Schunk's most important contributions is his patent titled "Metabolically Robust Analogs of CYP-eicosanoids for the Treatment of Cardiac Disease." This invention relates to compounds defined by a general formula that reflects the structure of bioactive lipid mediators derived from omega-3 polyunsaturated fatty acids (n-3 PUFAs). The patent details the metabolic robustness of these analogs and their application in both the treatment and prevention of cardiovascular diseases. Such advancements are crucial, given the increasing prevalence and impact of heart-related conditions worldwide.
Career Highlights
Throughout his career, Wolf-Hagen Schunk has had the opportunity to work with esteemed organizations that have fostered his research. Notably, he has been associated with the Max Delbrück Center for Molecular Medicine, a leading research institution focusing on the intersection of molecular medicine and cellular mechanisms. Furthermore, he has also contributed to the University of Texas System, where his collaborative work has helped advance the understanding of cardiovascular health.
Collaborations
In his journey, Schunk has collaborated with notable colleagues, including Robert Fischer and Anne Konkel. Their collective expertise has helped in refining research approaches and achieving significant milestones in medical innovation, particularly relating to heart health.
Conclusion
Wolf-Hagen Schunk exemplifies the spirit of innovation that drives advancements in medical science. His work on metabolically robust analogs for the treatment of cardiac diseases not only showcases his inventive talent but also reflects a commitment to bettering healthcare outcomes. As his research progresses, it is expected that his contributions will continue to play a vital role in developing new treatments for cardiovascular diseases.